Researchers from West Orange, N.J.-based RWJBarnabas Health, New Brunswick, N.J.-based Rutgers Cancer Institute, Boston-based Tufts Medical Center and the University of Manchester in England, have developed a risk prediction model for early-stage classic Hodgkin lymphoma.
The model is called the Early-stage Hodgkin International Prognostication Index and predicts a patient’s two-year progression-free survival, according to a June 19 news release from RWJBarnabas Health.
The organizations developed and validated the model using clinical trial data from more than 3,000 adult early-stage Hodgkin lymphoma patients across four international phase 3 trials and two real-world registry cohorts of more than 2,300 early-stage classic Hodgkin lymphoma patients.
The model uses common clinical data such as sex, tumor size, and hemoglobin and albumin levels to predict a patient’s chance of two-year survival.
The model’s development and validation data was published June 19 in NEJM Evidence.
